Dr. Hashemi Sadraei Discusses Biomarkers in HPV-Induced Tumors

Video

In Partnership With:

Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.

Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.

Hashemi Sadraei discusses a recent study that examined 201 patients with anal cancer, 321 patients with cervical cancer, and 358 patients with oropharyngeal cancer. Researchers sought to determine if, since the tumor ideology of these three groups are similar, if molecular patterns exist among them. Next-generation sequencing, immunohistochemistry, and in situ hybridization were used to compare the presence of mutations, amplification, and protein expression among the three tumor types.

The study showed that there are significant similarities, Hashemi Sadraei says. Neither mutations or protein expressions were found to be statistically different among the three tumors. Moreover, similar levels of PD-1/PD-L1 expression were found. Due to these findings, researchers may be able to explore new therapeutic options that could elicit responses in all three subgroups, Hashemi Sadraei says.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology